Journal of Clinical Oncology
Articles in this Issue
A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).
TPS8116 Background: Neoadjuvant chemo + anti–PD-1 checkpoint blockade, with/without adjuvant anti–PD-1, represents a new standard of care for pts with res...
Characterizing clinical outcomes and DNA co-alterations of ERBB2-amplified colorectal cancer.
3627 Background: A subset of colorectal cancer (CRC) features amplification (amp) of the ERBB2 gene. The prognostic role and treatment in these patients a...
Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).
TPS7567 Background: Treatment options have advanced for patients (pts) with TI-NDMM, but outcomes remain worse compared to pts with transplant-eligible ND...
Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA.
3584 Background: One challenge in cell-free DNA (cfDNA) profiling for genomic tumor profiling is the inability to confidently confirm the absence of actio...
Safety and efficacy of non-viral aPD1-MSLN JL-lightning–CAR-T in advanced malignant mesothelioma in a phase I trial.
2534 Background: CAR-T cells face challenges in solid tumors, including weak in vivo proliferation, immunosuppressive tumor microenvironments (TME), and l...
The efficacy of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancers: A single-center real-life data experience.
e16113 Background: Based on the CheckMate 577 study, one year of nivolumab treatment has become the standard for patients diagnosed with esophageal or gas...
Temporal trends in cancer-specific survival for early-onset gastric cancer: Insights from a 21-year cohort.
e22549 Background: Despite advancements in cancer care, Early-Onset Gastric Cancer (EOGC), defined as gastric cancer diagnosed in individuals under 50 yea...
Predictors of cardiotoxicity in breast cancer patients treated with doxorubicin/trastuzumab.
e24125 Background: Cardiotoxicity is a well-documented adverse effect of chemotherapy in breast cancer (BC) patients treated with anthracyclines such as d...
Open pilot of a culturally responsive, cognitive-behavioral intervention (PROWESS) for Black and Latino men receiving androgen deprivation therapy for prostate cancer.
e17009 Background: Black and Latino men face disproportionately higher risks prostate cancer (PC) and PC-related mortality compared to White men. Moreover...
The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).
8012 Background: Unresectable stage III NSCLC patients with large tumor volumes remain challenging. Our previous retrospective study has showed promising...
Comprehensive analysis of outcomes of patients with colorectal cancer in a racially diverse cohort.
3625 Background: Disparate outcomes have been reported among patients with colorectal cancer (CRC) as those with Medicare or Medicaid insurance and those...
PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: A prospective, multicenter clinical trial.
2616 Background: Low frequency of durable responses in patients treated with immune checkpoint inhibitors demands for taking complementary strategies in o...
The risk factors of immune-mediated liver injury caused by immune checkpoint inhibitors.
e14587 Background: Despite the fact that the majority of immune-mediated liver injuries caused by immune checkpoint inhibitors (ILICI) clinically present...
Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]).
542 Background: Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC), representing 10–15% of cases. HER2 ov...
Differences in patient characteristics, treatment patterns, and clinical outcomes of renal cell carcinoma patients in public vs private health care systems in Brazil: Insights from the LACOG 1120 registry.
4552 Background: Brazil's dual healthcare system presents unique challenges in addressing disparities in cancer care. Understanding the differences in cli...
A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers.
5597 Background: Copy number-high (CNH) ECs are characterized by high levels of copy-number alterations and TP53 mutations, and a...
Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC).
6015 Background: BV, an antibody-drug conjugate (ADC) targeting CD30, is hypothesized to deplete T regulatory cells (Tregs) that express CD30 and resensit...
Disparities in triple-negative breast cancer survival: A 2000-2021 retrospective SEER analysis of racial, histologic, and socio-demographic factors.
e13154 Background: Triple-negative breast cancer (TNBC) is a less common but highly aggressive subtype of breast cancer with poor prognosis and limited th...
From surgeon’s decision to multidisciplinary tumor board consensus: Evaluating treatment plan modifications.
e13543 Background: Multidisciplinary tumor boards (MTBs) are essential for optimizing cancer care through collaborative decision-making. However, the conc...
Use of adjuvant regimens with single-cytotoxic agents among women with stage II-III HER2-positive breast cancer.
e12526 Background: Use of paclitaxel alone with trastuzumab leads to excellent survival with T1 HER2+ breast cancer. The role of de-escalation of cytotoxi...
Prognostic prediction of combined pre- and post-operative ctDNA detection in non-small cell lung cancer.
e15050 Background: Circulating tumor DNA (ctDNA) serves as a valuable biomarker for monitoring relapse, with postoperative ctDNA shown to predict patient...
Effect of KRT3 on colorectal cancer growth through regulation glycolysis via the cebpd-LRRC8A-AKT signaling axis.
e15587 Background: Colorectal cancer (CRC) is one of the most common malignancies worldwide with high morbidity and mortality. Its development and progres...
Clinical characteristics of cancer-associated achalasia (CAA): A 25-year review from a cancer hospital.
e24034 Background: Achalasia is an uncommon, usually idiopathic disorder of esophageal motor function (annual incidence 1.6:100, 000). Achalasia associate...
Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography.
10514 Background: Allostatic load (AL), an indicator of chronic physiologic stress, is associated with increased breast cancer incidence and all-cause mor...
Feasibility of vaginal tampon versus swab in the collection of vaginal fluid for endometrial cancer testing.
e17617 Background: Abnormal uterine bleeding (AUB) is a cardinal symptom of endometrial cancer (EC). However, 90-95% of those with AUB will undergo invasi...